And more on South Korea's vaccine rollout.
As mentioned just a minute ago, AstraZeneca jabs started on Friday and Pfizer on Saturday.
The first people getting their shots are frontline medical workers treating COVID-19 patients in the capital region.
Lee Kyung-eun has the latest.
On the second day of South Korea's historic COVID-19 vaccination program, the country began rolling out Pfizer's vaccines at 9 AM.
The National Medical Center in Seoul took the first step, towards inoculating some 55-thousand COVID-19 front-line medical workers nationwide, using this first batch of Pfizer's vaccine.
The first recipient was a 51-year old female cleaner who works at the NMC's ICU, at 9:04 AM.
Throughout the day, some 3-hundred front-line medical workers in the capital region will be getting their jabs, including 1-hundred-99 workers at the NMC.
Along with doctors and nurses, faculty and staff are also eligible for the vaccinations.
The shots are injected with LDS or Low Dead Space Syringes, which the government officially approved on Saturday for extracting an extra one or two doses from each vaccine vial.
That would be up to six or seven for Pfizer,and 11 or 12 for AstraZeneca.
This first batch of Pfizer vaccines arrived on Friday from the global vaccine supply scheme COVAX, enough to inoculate some 58-thousand people.
Upon arrival, the vaccines were directly transported to 5 different vaccination centers nationwide, escorted by police and military.
After the vaccinations at NMC on Saturday, 4 of those facilities will be carrying out inoculations between March 3rd and 9th.
Staff in those facilities came to NMC on Saturday to learn the process of inoculation using Pfizer's vaccine, which requires cold chain storage, as well as a delicate thawing and diluting process.
Starting on the 8th, some 82 COVID-treating hospitals with more than 1-hundred-20 registered recipients will be carrying out the inoculations on-site to prevent staff shortage.
The government aims to complete giving the first dose by March 20th, and the second dose by April 10.
According to Phase 3 clinical data, Pfizer's vaccine shows a 95 percent efficacy.
The most common side effects include pain in the administered area and flu symptoms, most of which should go away in a few days.
Lee Kyung-eun, Arirang News.